% | $
Quotes you view appear here for quick access.

Jazz Pharmaceuticals Public Limited Company Message Board

  • b1g_brothr b1g_brothr Dec 19, 2013 5:23 PM Flag

    Why is JAZZ Surging in After Hours?

    The only news is it's buying some company nobody ever heard of with a drug nobody's heard of to treat a disease nobody's heard of. Typically the acquiring company sells off.

    I'll happily take the money, but that can't be what is moving the stock.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • maybe you need to do some DD? GENT drugs are approved in the EU only. Phase # here in the USA. SO the best is on the horizon. Never heard of JAZZ before 18 months ago. And would never had bought a pharma named "JAZZ" until I did my DD.
      GL2U..sounds like you will need some.

    • GENT for a billion is a great buy! I personally think the company is worth a lot more than that and it seems other investors agree.

      • 2 Replies to greenmachine_33364
      • if you look at GENTs chart you will see it was $7 in july of this year so I would say in Italy the word was out a long time ago and all the relatives bought. They may not have the insider rules we do but my bet is that jazz has been looking at it since july and was waiting fro europe approval on the drug and had already cut a price much earlier. Gents earnings next year are estimated to almost quadruple from this years and that is with Italian taxes but they will become a Irish company now. The press release said it would be earnings accretive next year and the stock imo has gone up for several reasons
        1) earnings accretive
        2) the drug will eventually be approved in the USA
        3) this gives Jazz more drugs in its arsenal so they aren't relying on one drug which will help expand the multiple people are willing to pay
        4) other drugs in GENT pipeline potential
        This will be another good add on as was the one earlier this year.

      • maybe. but I've never heard, read, seen or smelled an Italian pharma company let alone a bio-pharma one. But I'm not arguing with Mr Market either. This is a game changer.

128.41-4.39(-3.31%)12:02 PMEDT